On Tuesday, Shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS), included 4.55% and shut at $1.15 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $1.09 and $1.24. Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented preclinical data showing that the combination of its CNS-selective GABAA modulator ganaxolone and diazepam administered intravenously (IV) produced a synergistic effect in blocking pilocarpine-induced seizures in a benzodiazepine refractory model of status epilepticus (SE). Marinus is developing ganaxolone IV for the treatment of status epilepticus, a life-threatening medical emergency associated with high mortality and limited treatment options. The data was presented during a poster presentation at Neuroscience 2016, the annual meeting of the Society for Neuroscience, which occurred November 12 – 16, 2016 in San Diego, CA.
The poster entitled, “Ganaxolone and diazepam administered IV produce a synergistic anti-epileptic effect in treatment refractory model of status epilepticus,” was presented by Michael S. Saporito, Ph.D., a preclinical consultant to Marinus Pharmaceuticals. The data in the poster demonstrated that sub-therapeutic doses of diazepam and ganaxolone when administered in combination 15 minutes after onset of status epilepticus produced a partial or complete block of treatment-resistant status epilepticus in a rat model of SE, a clinically translatable model of this condition. Ganaxolone and diazepam plasma levels were measured alone and in combination and were identical, indicating that neither drug affected the pharmacokinetic disposition of the other. In addition, the study suggests that the synergistic enhancement of anti-epileptic activity occurred at the level of the GABAA receptor.
Shares of Liberty Global plc – Class C Ordinary Shares (NASDAQ:LBTYK), added 0.28% and shut at $32.05 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $31.92 and $32.44. The association’s commercial center capitalization is $20.42 Billion with the general uncommon loads of 639.00 million. John Reid has been confirmed as Chief Executive Officer of C&W Communications (“C&W”, or the “Company”) effective November 7, 2016. C&W serves 18 countries and is one of the leading full service telecommunications and entertainment providers in the Caribbean and Latin America. The Company was recently attained by Liberty Global plc “Liberty Global”, the world’s leading international TV and broadband company.
“This is a time of meaningful change and development for C&W, and I am excited for the expertise and continuity that John brings to this growing region,” said Mike Fries, CEO of Liberty Global. Reid is tasked with aligning the former UK-based company with Liberty’s Latin America and Caribbean (“LiLAC Group”) division, while strengthening the Company’s growth opportunities, in particular triple-play, mobile data and fixed-mobile convergence, and seizing on the noteworthybusiness-to-business and wholesale opportunities in the region.